Hans-Peter Kiem (Fred Hutch)
February 11, 2021 07:31 AM ESTUpdated February 12, 10:37 AM
Financing

Sana gets a com­peti­tor as Take­da, 5AM pour $170M in­to a Fred Hutch pi­o­neer's quest to un­seat CAR-T, ex vi­vo gene ther­a­py

Jason Mast

Editor

Over the last decade, Hans-Pe­ter Kiem, the Fred Hutch stem cell bi­ol­o­gist, and 5AM Ven­tures chief Kush Par­mar found­ed a slate of promi­nent biotechs, in­clud­ing …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Mi­crosoft-backed Enve­da rais­es $130M for drugs in I&I, obe­si­ty and oth­er ar­eas

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times